2-Pivaloyl-benzothiazol | 33429-15-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 2-Pivaloyl-benzothiazol
• 英文别名: 1-benzothiazol-2-yl-2,2-dimethyl-propan-1-one；1-(1,3-Benzothiazol-2-yl)-2,2-dimethylpropan-1-one
• CAS: 33429-15-1
• 化学式: C₁₂H₁₃NOS
• 分子量: 219.307
• InChiKey: QYETYSUDZJCLCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Pivaloyl-benzothiazol 、 正丁基锂 以46%的产率得到
  参考文献：
  名称：

  CHIKASHITA, HIDENORI;ISHIHARA, MASAYUKI;ITOH, KAZUYOSHI, HETEROCYCLES, 1985, 23, N 10, 2467-2472

  摘要：

  DOI：
• 作为产物：
  描述：

  三甲基乙酸乙酯 、 2-苯并噻唑基锂 以 四氢呋喃 为溶剂， 以69%的产率得到2-Pivaloyl-benzothiazol
  参考文献：
  名称：

  Chikashita, Hidenori; Ishihara, Masayuki; Itoh, Kazayoshi, Heterocycles, 1985, vol. 23, # 10, p. 2467 - 2472

  摘要：

  DOI：

文献信息

• General Reactivity of 2-Lithiobenzothiazole to Various Electrophiles and the Use as a Formyl Anion Equivalent in the Synthesis of α-Hydroxy Carbonyl Compounds
  作者：Hidenori Chikashita、Megumi Ishibaba、Keiji Ori、Kazuyoshi Itoh

  DOI：10.1246/bcsj.61.3637

  日期：1988.10

  demonstrated by its reaction with phenacyl halides and 5-chloro-2-pentanone leading to the formation of benzothiazolyl-substituted small-ring ethers. In order to demonstrate the value of 2-lithiobenzothiazole as a masked formyl anion, 2-(α-hydroxyalkyl)benzothiazoles were transformed into α-hydroxy carbonyl compounds in three reaction steps without masking the α-hydroxy groups. Quaternization of various

  2-锂硫代苯并噻唑与各种亲电子试剂如醛、酮、羧酸酯、内酯、腈和酰胺的反应提供了预期的加成和取代产物。三甲基甲硅烷基氯很容易与苯并噻唑阴离子反应生成 2-三甲基甲硅烷基苯并噻唑，而常见的烷基卤化物，包括伯碘化物和苄基卤化物，以及环氧化物，不与阴离子反应。阴离子的这种特征亲核性也通过它与苯甲酰卤和 5-氯-2-戊酮的反应导致苯并噻唑基取代的小环醚的形成得到证实。为了证明 2-硫代苯并噻唑作为掩蔽甲酰基阴离子的价值，2-(α-羟基烷基)苯并噻唑在三个反应步骤中转化为α-羟基羰基化合物，而不会掩盖α-羟基。各种 2-(α-羟烷基)苯并噻唑与甲基碘在 DMF 中季铵化得到相应的 2-(α-羟烷基)-3-甲基苯...
• Homolytic acylation of benzothiazole. A diagnostic criterion for the presence of acyl radicals
  作者：T. Caronna、R. Galli、V. Malatesta、F. Minisci

  DOI：10.1039/j39710001747

  日期：——

  Benzothiazole is acylated by acyl radicals obtained from aldehydes selectively in the 2-position. The nucleophilic character of acyl radicals is also confirmed by the higher reactivity of the 6-nitro-derivative. The high reactivity is useful in syntheses; this reaction can also be used as a diagnostic criterion for revealing the presence of acyl radicals in the oxidation of aldehydes with various oxidizing

  苯并噻唑被从2-位上的醛中选择性地获得的酰基自由基酰化。酰基自由基的亲核特性还通过6-硝基衍生物的更高反应性得到了证实。高反应活性可用于合成；该反应也可以用作诊断标准，以揭示在用各种氧化剂（O 2，Ce IV，Cr VI或Mn VI）氧化醛的过程中存在酰基。
• Organic Compounds and Their Uses
  申请人：Brandl Trixi

  公开号：US20080045530A1

  公开（公告）日：2008-02-21

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

  本申请描述了有机化合物，可用于治疗、预防和/或改善人类疾病。
• Inhibitors of serine proteases, particular HCV NS3-NS4A protease
  申请人：Pitlik Janos

  公开号：US20070292933A1

  公开（公告）日：2007-12-20

  The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及抑制丝氨酸蛋白酶活性的化合物，特别是乙型肝炎病毒NS3-NS4A蛋白酶的活性。因此，它们通过干扰乙型肝炎病毒的生命周期而起作用，并且也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于体外使用还是用于治疗患有HCV感染的患者的给药。本发明还涉及通过给予含有本发明化合物的组合物来治疗患有HCV感染的患者的方法。本发明还涉及制备这些化合物的过程。
• INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
  申请人：Pitlik Janos

  公开号：US20100173851A1

  公开（公告）日：2010-07-08

  The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的化合物。因此，它们通过干扰丙型肝炎病毒的生命周期发挥作用，并且也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于体外使用还是用于治疗HCV感染的患者的给药。本发明还涉及通过给予含有本发明化合物的组合物来治疗患者的HCV感染的方法。本发明还涉及制备这些化合物的方法。